Viatris and Biocon Launch First Interchangeable Insulin in the U.S.

by April Breyer Menon | Nov 30, 2021

On November 16, 2021, Viatris and Biocon announced the launch of two interchangeable insulin glargine products, a branded version, Semglee® (insulin glargine-yfgn) injection, and an unbranded version, Insulin Glargine (insulin glargine-yfgn) injection, both of which...

Venable’s BiologicsHQ Monthly Injection – October 2021

by April Breyer Menon | Nov 10, 2021

Download PDF Download...

FDA Approves Boehringer Ingelheim’s Cyltezo® as Interchangeable with Humira®

by April Breyer Menon | Oct 25, 2021

On October 15, 2021, the FDA approved Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm) as interchangeable with AbbVie’s Humira® (adalimumab) for many of Humira’s approved indications. As an interchangeable, Cyltezo can be automatically substituted for Humira...

U.S. Patent Legal Landscape Outlook

by April Breyer Menon | Oct 22, 2021

Ha Kung Wong, Wei Campbell, and Christine Cochran gave a LSPN Live presentation titled “US Patent Legal Landscape Outlook: What are the Main Challenges Facing the US Patent System and how do we Prepare for them?” where they discussed recent Supreme...

Venable’s BiologicsHQ Monthly Injection – September 2021

by April Breyer Menon | Oct 12, 2021

Download PDF Download...

2021 Patent Caselaw Roundup – Lawline CLE

by April Breyer Menon | Oct 11, 2021

Christopher Loh taught a Lawline CLE updating in-house and outside counsel on the latest developments in patent case law. The CLE includes a review of the Supreme Court’s Arthrex decision and its effects on the logistics of inter partes review...

« Older Entries

Next Entries »

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.